SureNano Science Targets Obesity Market with Novel GEP-44 Peptide

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) is emerging as a promising player in the rapidly growing GLP-1 therapy market for obesity and metabolic disease. The company has transitioned into a pharmaceutical-focused platform anchored by its patented GEP-44 peptide, which targets metabolic disease. Preclinical data for GEP-44 demonstrates meaningful weight loss, improved glucose control, and a favorable tolerability profile relative to existing GLP-1 therapies like Ozempic®, Wegovy®, and Mounjaro®. SureNano's vertically integrated model combines therapeutic development with delivery technologies, supporting differentiation through potential non-injectable formats, which could address a key limitation of current treatments. The company is advancing GEP-44 through a defined regulatory pathway, including IND-enabling studies and planned clinical trials, positioning itself as an agile entrant in a market projected to grow significantly over the coming years. Through its acquisition of GlucaPharm Inc., SureNano holds an exclusive license to develop GEP-44, a novel peptide discovered at Syracuse University. For more details, Read More>>.

The news release also highlights SureNano's exposure to the expanding GLP-1 and obesity treatment markets, which are projected to grow significantly. The company's newsroom at https://nnw.fm/SURNF provides the latest updates. This content is disseminated on behalf of SureNano Science Ltd. and may include a paid advertisement. The forward-looking information section outlines risks and uncertainties, emphasizing that actual results might differ materially from projections. Investors are encouraged to conduct their own analysis and consult with advisors. NetworkNewsWire (NNW) is a specialized communications platform within the Dynamic Brand Portfolio that delivers customized corporate communications solutions.